Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - tropicamide, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; purified water - to produce mydriasis and cycloplegia.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - pilocarpine nitrate, quantity: 20 mg/ml - eye drops, solution - excipient ingredients: purified water - chronic non-congestive glaucoma and as a miotic for reversing the action of the weaker mydriatics.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - lidocaine hydrochloride monohydrate, quantity: 40 mg/ml; fluorescein sodium, quantity: 2.5 mg/ml - eye drops, solution - excipient ingredients: purified water; hydrochloric acid; povidone - as a diagnostic stain and topical anaesthetic combined, minims lignocaine and fluorescein is intended primarily to facilitate goldmann applanation tonometry.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - cyclopentolate hydrochloride, quantity: 10 mg/ml - eye drops, solution - excipient ingredients: purified water; hydrochloric acid - to produce mydriasis and cycloplegia

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - atropine sulfate monohydrate, quantity: 10 mg/ml - eye drops, solution - excipient ingredients: hydrochloric acid; purified water - to produce mydriasis and cycloplegia

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - timolol maleate, quantity: 3.42 mg/ml (equivalent: timolol, qty 2.5 mg/ml) - eye drops, solution - excipient ingredients: benzalkonium chloride; monobasic sodium phosphate; dibasic sodium phosphate dodecahydrate; water for injections; sodium hydroxide - timoptol ophthalmic solution is indicated for the reduction of elevated intraocular pressure. in clinical trials it has been shown to reduce intraocular pressure in: patients with ocular hypertension - patients with chronic open-angle glaucoma - aphakic patients with glaucoma.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - timolol maleate, quantity: 6.83 mg/ml (equivalent: timolol, qty 5 mg/ml) - eye drops, solution - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate dodecahydrate; sodium hydroxide; benzalkonium chloride; water for injections - timoptol ophthalmic solution is indicated for the reduction of elevated intraocular pressure. in clinical trials it has been shown to reduce intraocular pressure in: patients with ocular hypertension - patients with chronic open-angle glaucoma - aphakic patients with glaucoma.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - tropicamide, quantity: 10 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; benzalkonium chloride; purified water; disodium edetate; hydrochloric acid; sodium hydroxide - indications as at 14 july 2003 : used to produce mydriasis and cycloplegia for diagnostic purposes.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - tropicamide, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; sodium hydroxide; disodium edetate; purified water; benzalkonium chloride; hydrochloric acid - indications as at 14 july 2003 : used to produce mydriasis and cycloplegia for diagnostic purposes.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - dexamethasone, quantity: 1 mg/ml - eye drops, suspension - excipient ingredients: dibasic sodium phosphate; polysorbate 80; disodium edetate; sodium chloride; benzalkonium chloride; purified water; hypromellose; citric acid monohydrate; sodium hydroxide - indications as at 16 jan 2005 : steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in oedema and inflammation; acute and chronic anterior uveitis; corneal injury from chemical radiation or thermal burns or penetration of foreign bodies.